執業經驗
Ultragenyx files ANDA patent suit against three generic-drug manufacturers involving DOJOLVI®Jones Day represents plaintiff Ultragenyx Pharmaceutical Inc. in asserting claims of patent infringement under the Hatch-Waxman Act involving a life-saving pharmaceutical product known as Dojolvi® (triheptanoin) against three generic manufacturers seeking to market generic versions of triheptanoin oral liquid. AbbVie alleges former scientist and his new employer stole trade secrets relating to Bruton's tyrosine kinase (BTK) degradersJones Day is representing AbbVie Inc. in asserting claims for trade secret misappropriation under the Defend Trade Secrets ACT (DTSA) against its former scientist and his new employer, BeiGene, a pharmaceutical company located in China. P&G asserts aluminum-free deodorant patents against Dr. SquatchJones Day is representing plaintiff The Procter & Gamble Company ("P&G") in a patent infringement dispute, asserting five patents relating to aluminum-free deodorants and defending five IPR petitions at the U.S. Patent Trial and Appeal Board (PTAB) filed by defendants after the filing of the complaint. Fred Hutchinson Cancer Research Center defeats IPR petition brought by Miltenyi Biomedicine GmbHJones Day represented patent owner Fred Hutchinson Cancer Research Center, on behalf of exclusive licensee Bristol Myers Squibb, in successfully defeating a patent challenge in an inter partes review (IPR) proceeding brought by petitioners Miltenyi Biomedicine GmbH and Miltenyi Biotec Inc. ("Miltenyi") in the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB). AbbVie sues former scientist and his new employer for trade secret misappropriation involving ADCsJones Day is representing AbbVie Inc. in asserting claims for trade secret misappropriation under the Defend Trade Secrets Act (DTSA) against its former scientist and his new employer Adcentrx, a biotechnology company located in San Diego. Merck wins bench trial over patent term extension issue in Hatch-Waxman multi-party dispute involving BRIDION®Jones Day is representing Merck Sharp & Dohme, B.V. in Hatch-Waxman patent infringement actions originally against 16 generic drug maker defendant groups, relating to the defendant groups' submissions of Abbreviated New Drug Applications (ANDA) to the FDA seeking approval of generic versions of BRIDION®, a first-in-class agent for the reversal of certain types of neuromuscular blockade induced in adults undergoing surgery. Procter & Gamble settles patent infringement claims related to teeth whitening stripsJones Day represented The Procter & Gamble Company in a patent infringement lawsuit brought by CAO Group for alleged infringement of patents relating to teeth whitening strips. Cohesity disposes of six-patent litigation brought by adverse competitor CommvaultJones Day successfully represented Cohesity Inc. ("Cohesity") and obtained dismissal in a six-patent, competitor suit filed by Commvault Systems in April 21, 2020. Merck unit resolves DJ action involving pneumococcal vaccine patentsJones Day represented Merck Sharp & Dohme Corp. in an action in Delaware district court against Pfizer (through its subsidiaries including Wyeth, LLC) involving several patents on Wyeth’s vaccine technology. Sloan Kettering and Juno Therapeutics win over $1.1 billion after jury verdict and post-trial motions in patent dispute with Kite Pharma/Gilead involving CAR-T therapyOn behalf of patentee Sloan Kettering Institute and exclusive licensee Juno Therapeutics (a subsidiary of Celgene Corporation, a Bristol Myers Squibb company), Jones Day and co-counsel prevailed in a jury trial that spanned eight days and involved 22 witnesses, wherein the jury awarded our clients $752 million in compensation for the infringement of their patents by Kite Pharma, Inc. (a Gilead Sciences, Inc. company) through the making and selling of its infringing CAR-T therapy, YESCARTA®. Adocia prevails in biopharma license agreement dispute in international arbitrationJones Day won a binding arbitration award for French biopharmaceutical company, Adocia S.A., in a license agreement dispute against Eli Lilly and Company. Celgene acquires Juno Therapeutics for $9 billionOn behalf of Celgene Corporation, Jones Day conducted a large-scale intellectual property due diligence review and evaluation of matters related to its definitive merger agreement and acquisition of Juno Therapeutics for approximately $9 billion, including Juno’s technology related to CAR-T and TCR cellular immunotherapeutics for use in oncology and other indications. GTAT protects trade secrets, obtains restraining order against former employeeJones Day assisted GT Advanced Technologies (GTAT), a leader in providing technology solutions to the solar industry, in pursuing claims of trade secret misappropriation and breach of contracts against a former employee when he departed the company after over a decade of exposure to its trade secrets and confidential information. H&R Block defeats patent infringement case brought by UnilocJones Day successfully defended H&R Block, Inc. in a multi-patent infringement lawsuit brought by Uniloc USA, Inc. The following represents experience acquired prior to joining Jones Day.
Represented an industrial crystal growth company in a trade secret dispute involving specialized equipment and processes for the purification of materials for the solar industry. Engaged is early mediation and obtained favorable settlement.
Represented an American toy and board game company against allegations of copyright infringement of board game characters. Obtained favorable settlement.
Represented a global consumer electronics company accused of infringing a patent involving the processing of compute instructions in the Western District of Wisconsin. Obtained favorable judgment.
Represented a global sportswear and athletic goods company in a trademark and trade dress matter in the District of Massachusetts. Obtained desirable stay of proceedings.
Represented a global networking company in patent litigation involving internet traffic transmissions in the Northern District of California. Obtained early dismissal of matter.
Represented a major semiconductor company in a jury trial in the Central District of California involving the infringement of several patents related to high-speed networking devices used in data centers. Obtained a favorable outcome after a two-year-long patent infringement case. The Federal Circuit affirmed the permanent injunction and the underlying findings of infringement and validity.
Represented a major networking equipment manufacturer accused of infringing four patents related to point-to-point network communications in the Northern District of California. Obtained early dismissal of matter.
Represented a global sportswear and athletic goods company in a patent infringement case in the Central District of California involving athlete-sponsored contests for designing shoes using a network-based graphical software tool. Obtained favorable settlement on behalf of client.
Represented global processor company accused of infringing a family of Wi-Fi patents in the Central District of California. Obtained a favorable claim construction ruling and summary judgment of noninfringement that was upheld on appeal.
Represented a branded pharmaceutical company in ANDA litigation involving Niacin formulations in the District of Delaware. Obtained favorable settlements.
Represented a software manufacturer accused of infringing a patent in the Central District of California in obtaining a favorable claim construction ruling and summary judgment ruling.
Represented Radio Frequency Identification (RFID) tag manufacturer against accusations of infringing 14 patents relating to various aspects of RFID tags in the District of North Dakota in obtaining favorable claim construction and summary judgment rulings or dismissal of 13 of the 14 patents, with the final patent submitted to reexamination proceedings.
Represented pharmaceutical company accused of infringing two patents relating to cyclosporine formulations in the District of Delaware through trial and on appeal, ultimately prevailing in the Federal Circuit, which affirmed the district court's grant of judgment as a matter of law.
